Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorChris Goss
About this trial
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Eligibility criteria
Qualifiers
≥ 16 years of age on day of study visit
Documentation of CF Diagnosis
Able to expectorate sputum
Percent predicted FEV1 ≥ 30%
Disqualifiers
History of solid organ transplantation
History of active malignancy (or treatment for malignancy) in 12 months prior to the study visit
Pregnant
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Chris Goss
Lead sponsor
Seattle Children's Hospital
Sponsor institution
Cystic Fibrosis Foundation
Collaborator
University of Pennsylvania
Collaborator
Source ClinicalTrials.gov